Compare BTBT & CUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTBT | CUVL |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | Australia |
| Employees | N/A | 16 |
| Industry | Finance: Consumer Services | Miscellaneous |
| Sector | Finance | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 427.6M | 374.2M |
| IPO Year | 2017 | N/A |
| Metric | BTBT | CUVL |
|---|---|---|
| Price | $1.70 | $6.14 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 30.6M | 17.6K |
| Earning Date | 05-15-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $113,560,320.00 | N/A |
| Revenue This Year | $38.96 | N/A |
| Revenue Next Year | $89.41 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.10 | N/A |
| 52 Week Low | $1.18 | $5.95 |
| 52 Week High | $4.55 | $8.20 |
| Indicator | BTBT | CUVL |
|---|---|---|
| Relative Strength Index (RSI) | 60.32 | 38.85 |
| Support Level | $1.54 | N/A |
| Resistance Level | $1.74 | $6.82 |
| Average True Range (ATR) | 0.14 | 0.45 |
| MACD | 0.02 | -0.09 |
| Stochastic Oscillator | 91.09 | 2.67 |
Bit Digital Inc is engaged in the Bitcoin mining business, Ethereum staking activities and specialized cloud-infrastructure services for artificial intelligence applications through its wholly owned subsidiaries. Its mining platform operates with the primary intent of accumulating bitcoin which may sell for fiat currency from time to time depending on market conditions. The Company has four reportable segments: digital asset mining, cloud services, colocation services, and ETH Staking. It generates majority of its revenue from digital asset mining.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.